Rabıa SAGIR

Dr. Rabıa SAGIR

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2020 in European Journal of Rheumatology
Verified
Journal Article
Open access
AKAhmet Karataş
Ahmet Karataş
AGAybüke Nisa Gerçek
Aybüke Nisa Gerçek
BÖBurak Öz
Burak Öz
NGNEVZAT GOZEL
NEVZAT GOZEL
RSRabıa SAGIR
Rabıa SAGIR
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Objective: Secukinumab, a new treatment agent, selectively neutralizes interleukin (IL)-17A. It is used in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. It is known that the agents used in the treatment of rheumatic diseases have effects on hematological parameters. In this study, we aimed to determine whether hematological parameters are affected in secukinumab therapy in patients with AS and PsA. Methods: Thirty-six patients on secukinumab treatment were included in the study by scanning the database of our hospital. Data on patients’ age, gender, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine values, and additional drug treatments were recorded from our database. The 0- and 6-month values of patients were analyzed. Results: Sixteen males (44.4%) and 20 females (55.6%) were included in our study. The average age was calculated to be 39.8±8.9 years. Of these, 30 patients receiving secukinumab treatment were diagnosed with AS, and 6 patients were diagnosed with PsA. Twenty-three patients (63.9%) were continued with secukinumab treatment at the 6th month. When CBC, glucose, urea, creatine, AST, ALT, ESR, CRP, and uric acid values of the patients at 0 and 6 months were compared, there was no significant difference. Conclusion: In our study, no significant difference was found between 0 and 6 months in terms of CBC, AST, ALT, urea, creatinine, uric acid, glucose, CRP, and ESR levels in patients receiving secukinumab. However, an increase in hemoglobin values was observed in patients who continued the treatment. These results may suggest that secukinumab treatment has no negative effects on hematological parameters. Cite this article as: Karataş A, Gerçek AN, Öz B, Gözel N, Pişkin Sağır R, Gür M, et al. The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis. Eur J Rheumatol 2020; 7(4): 169-72.

18 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TOTuğba OCAK
Tuğba OCAK
BYBurcu Yagiz
Burcu Yagiz
BOBirol Ocak
Birol Ocak
ÖYÖzge Yoğurtçu
Özge Yoğurtçu
FBFatma Başıbüyük
Fatma Başıbüyük
YPYavuz Pehlivan
Yavuz Pehlivan
Background: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug’s survival time and the efficacy and safety of secukinumab treatment in this specific patient group. Methods: This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA. Results: The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder. Conclusions: In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.

27 August 2024 in Türk Fizyoterapi ve Rehabilitasyon Dergisi
Verified
Journal Article
Closed access
SYSongul Baglan Yentur
Songul Baglan Yentur
GDGulnihal Deniz
Gulnihal Deniz
ZEZübeyde Ercan
Zübeyde Ercan
FBFurkan Bilek
Furkan Bilek
RSRabıa SAGIR
Rabıa SAGIR
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Purpose: This study was designed to investigate the effects of telerehabilitation on fatigue, depression, anxiety, disease activity, sleep quality and quality of life in patients with rheumatic diseases. Methods: This study included 28 patients with rheumatic diseases. Patients were divided into two groups as intervention group (IG) (n=16) and control group (CG) (n=12). Both groups kept on their regular medical care and an IG group additionally had exercise program. An exercise program including strengthening, stretching, breathing, posture and relaxation exercises was practiced to the IG via video-conference method while no additional therapy was applied to the CG. Assessments were performed using SurveyMonkey to avoid face to face connection. Anxiety and depression were assessed with Hospital Anxiety and Depression Scale (HADS), fatigue was assessed with Fatigue Severity Scale (FSS), sleep quality was assessed with Pittsburg Sleep Quality Index (PSQI) and quality of life was assessed with Health Assessment Questionnaire (HAQ). Additionally, disease activity was evaluated with disease-specific measurements. Results: Significant differences were found in anxiety (p=0.009), fatigue (p=0.003) and sleep quality (p=0.011) in group-by-time assessments in IG while no significant group-by-time difference were observed in any assessments in CG (p>0.05). No significant differences was observed in delta measurements of fatigue, quality of life, depression, anxiety and sleep quality within groups although patients in IG had better outcomes for all parameters compared to CG (p>0.05). Conclusion: Telerehabilitation was found to be a safe and effective method for patients with rheumatic diseases.

26 October 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
AKAhmet Karataş
Ahmet Karataş
RSRabıa SAGIR
Rabıa SAGIR
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
HDHüseyi̇n Edi̇z Dalkiliç
Hüseyi̇n Edi̇z Dalkiliç
GCGerçek Can
Gerçek Can
FÖFatoş Önen
Fatoş Önen
Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine whether the body mass index (BMI) is involved in the response to rituximab in rheumatoid arthritis (RA). Materials and methods: This multicenter retrospective study included 206 RA patients who received rituximab from the Turkish Biologic (TURKBIO) registry between 2011 and the end of May 2017. Demographic and clinical data including age, sex, disease type, disease duration, and previous or current treatment with disease-modifying antirheumatic drugs (DMARDs) and biological drug durations are stored in the database. Patients with a BMI ?30 kg/m2 were classified as obese, and patients with a BMI <30 kg/m2 were classified as nonobese. Kaplan-Meier survival analysis was performed to estimate the drug survival. The subgroups were compared using the log-rank test. Results: The mean BMI of 206 patients included in the study was 27.05 (17.2?43.4) kg/m2. There were 59 (28.6%) patients in the obese group and 147 (71.4%) patients in the nonobese group. The mean age, female percentage, and baseline disease activity score 28 (DAS28) were higher in the obese group than in the nonobese group. However, the ?DAS28 at both 6 and 12 months were not significantly different between the groups (p = 0.785 and p = 0.512, respectively). Patient pain Visual Analogue Scale (VAS), patient fatigue VAS, and patient global VAS scores were also significantly higher at baseline in the obese group (p = 0.003, p = 0.006, and p = 0.006, respectively). However, no significant difference was found in terms of changes in patient pain VAS, patient fatigue VAS, patient global VAS and physician global VAS scores at 6 and 12 months compared to those at baseline. Rituximab treatment was ongoing for 71.2% of the obese and 63.3% of the nonobese patients (p = 0.279). The median drug survival duration was 77 months in the obese group and 62 months in the nonobese group (p = 0.053). The estimated drug survival rates for rituximab were not statistically significantly different in the obese and nonobese groups. Rituximab-related side effects were also similar between the groups. Conclusion: In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that obesity does not alter drug survival for rituximab and response rates, in RA and rituximab may be a favorable treatment agent in patients with RA and obesity.

20 June 2023 in Rheumatology Quarterly
Verified
Journal Article
Closed access
MGMustafa Gur
Mustafa Gur
MAMESUDE SEDA AYDOĞDU
MESUDE SEDA AYDOĞDU
RSRabıa SAGIR
Rabıa SAGIR
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
AKAylin Dolu Karaca
Aylin Dolu Karaca
AKAhmet Karataş
Ahmet Karataş
Aim:The second-to fourth-digit ratio (2D:4D), the ratio of the second finger length to the fourth finger length, is associated with exposure to prenatal sex steroids. Rheumatoid arthritis (RA) is more common in women, suggesting the effect of hormonal factors. The aim of the present study was to determine whether 2D:4D, which is associated with sex hormone levels, is affected in patients with RA. Material and Methods:Digital images of the right and left hands of 205 RA patients (mean age 47.8±11.3 years; 84% female) and 205 age and gender matched healthy controls (mean age 47.3±11.6 years; 84% female) were obtained. 2D:4D was calculated by dividing the 2nd digit length by the 4th digit length. The 2D:4D difference between the right and left hand (ΔR-L 2D:4D) was obtained by subtracting the left hand 2D:4D ratio from the right hand 2D:4D ratio. Conclusion:The detected 2D:4D ratio differences suggest that prenatal estrogen/androgen balance may be altered in female patients with RA. To the best of our knowledge, this is the first study to evaluate 2D:4D change in patients with RA. Results:No difference was found between patients with RA and the control group in terms of the 2D:4D ratio in the right and left hand. In female patients with RA, ΔR-L 2D:4D was higher compared with the control group. For both hands, the 2D:4D increase rate in women compared to men was higher in patients with RA compared to the control groups.

1 April 2021 in Ulusal Romatoloji Dergisi
Verified
Journal Article
Closed access
AKAhmet Karataş
Ahmet Karataş
BÖBurak Öz
Burak Öz
RSRabıa SAGIR
Rabıa SAGIR
MGMustafa Gur
Mustafa Gur
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA